Detection of recurrent pancreatic cancer: Comparison of FDG-PET with CT/MRI

doi:10.1159/000085281

Pancreatology

Volume 5, Issues 2–3, 2005, Pages 266-272

https://doi.org/10.1159/000085281 Get rights and content

Abstract

Objective: To determine the value of fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for the detection of recurrent pancreatic cancer in comparison to computed tomography (CT) and magnetic resonance imaging (MRI). Methods: Thirty-one patients with suspected recurrence after surgery were included. Inclusion criteria were sudden weight loss, pain or increased CA 19-9 levels. FDG-PET was performed in all patients. After visual analysis, maximal standardized uptake values (SUVmax) were determined by placing regions of interest on the pancreas bed. Additionally, all patients underwent contrast-enhanced multidetector CT (n = 14) or MR (n = 17) imaging. Positive findings at FDG-PET or CT/MRI were compared to follow-up. Results: All patients relapsed. Of 25 patients with local recurrences upon follow-up, initial imaging suggested relapse in 23 patients. Of these, FDG-PET detected 96% (22/23) and CT/MRI 39% (9/23). Local SUVmax ranged from 2.26 to 16.9 (mean, 6.06). Among 12 liver metastases, FDG-PET detected 42% (5/12). CT/MRI detected 92% (11/12) correctly. Moreover, 7/9 abdominal lesions were malignant upon follow-up of which FDG-PET detected 7/7 and CT/ MR detected none. Additionally, FDG-PET detected extra-abdominal metastases in 2 patients. Conclusion: In patients suspected of pancreatic cancer relapse; FDG-PET reliably detected local recurrences, whereas CT/MRI was more sensitive for the detection of hepatic metastases. Furthermore, FDG-PET proved to be advantageous for the detection of nonlocoregional and extraabdominal recurrences.

References (25)

JS Barkin et al.
Diagnostic approach to pancreatic cancer
Gastroenterol Clin North Am
(1999)
H Oettle et al.
Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer
Cancer
(2002)
AD Jacobs
Gemcitabine-based therapy in pancreas cancer: Gemcitabine-docetaxel and other novel combinations
Cancer
(2002)
KJ Mortele et al.
Postoperative findings following the Whipple procedure: Determination of prevalence and morphologic abdominal CT features
Eur Radiol
(2000)
F Safi et al.
Prognostic value of CA 19-9 serum course in pancreatic cancer
Hepatogastroenterology
(1998)
C Franke et al.
18-FDG positron emission tomography of the pancreas: Diagnostic benefit in the follow-up of pancreatic carcinoma
Anticancer Res
(1999)
H Jadvar et al.
Evaluation of pancreatic carcinoma with FDG PET
Abdom Imaging
(2001)
T Higashi et al.
Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) - Usefulness and limitations in ‚clinical reality’
Ann Nucl Med
(2003)
E Lopez Hanninen et al.
Prospective evaluation of pancreatic tumors: Accuracy of MR imaging with MR cho-langiopancreatography and MR angiography
Radiology
(2002)
AE Hanbidge
Cancer of the pancreas: The best image for early detection — CT, MRI, PET or US?
Can J Gastroenterol
(2002)

D Delbeke

Oncological applications of FDG PET imaging

J Nucl Med

(1999)

K Koyama et al.

Diagnostic usefulness of FDG PET for pancreatic mass lesions

Ann Nucl Med

(2001)

Cited by (138)

Computed Tomography-based Radiomics Evaluation of Postoperative Local Recurrence of Pancreatic Ductal Adenocarcinoma
2023, Academic Radiology
To develop and validate an effective model for identifying patients with postoperative local disease recurrence of pancreatic ductal adenocarcinoma (PDAC).
A total of 153 patients who had undergone surgical resection of PDAC with regular postoperative follow-up were consecutively enrolled and randomly divided into training (n = 108) and validation (n = 45) cohorts. The postoperative soft-tissue biopsy results or clinical follow-up results served as the reference diagnostic criteria. Radiomics analysis of the postoperative soft-tissue was performed on a commercially available prototype software using portal vein phase image. Three models were built to characterize postoperative soft tissue: computed tomography (CT)-based radiomics, clinicoradiological, and their combination. The area under the receiver operating characteristic curves (AUC) was used to evaluate the differential diagnostic performance. A nomogram was used to select the final model with best performance. One radiologist's diagnostic choices that were made with and without the nomogram's assistance were evaluated.
A seven-feature–combined radiomics signature was constructed as a predictor of postoperative local recurrence. The nomogram model combining the radiomics signature with postoperative CA 19-9 elevation showed the best performance (training cohort, AUC = 0.791 [95%CI: 0.707, 0.876]; validation cohort, AUC = 0.742 [95%CI: 0.590, 0.894]). In the validation cohort, the AUC for differential diagnosis was significantly improved for the combined model relative to that for postoperative CA 19-9 elevation (AUC = 0.742 vs. 0.533, p < 0.001). The calibration curve and decision curve analysis demonstrated the clinical usefulness of the proposed nomogram. The diagnostic performance of the radiologist was not significantly improve by using the proposed nomogram (AUC = 0.742 vs. 0.670, p = 0.17).
The combined model using CT radiomic features and CA 19-9 elevation effectively characterized postoperative soft tissue and potentially may improve treatment strategies and facilitate personalized treatment for PDAC after surgical resection.
18F-Fluorodeoxyglucose-PET-Computerized Tomography and non-Fluorodeoxyglucose PET-Computerized Tomography in Hepatobiliary and Pancreatic Malignancies
2022, PET Clinics
Pancreatic Adenocarcinoma: Diagnostic Errors, Contributing Factors and Solutions
2022, Academic Radiology
The purpose of this article is to review diagnostic errors in preoperative and post-operative imaging for pancreatic ductal adenocarcinoma (PDAC), discuss contributing factors, and provide solutions that minimize errors. Accurate radiological staging and restaging of PDAC dictates surgical management and errors can have significant negative effects on patient care, such as missed vessel involvement or metastatic disease that would preclude surgery. Familiarity with these errors and their contributing factors improves diagnostic accuracy and ultimately leads to improved patient outcomes.
Pancreatic Ductal Adenocarcinoma
2022, Oncologic Imaging: A Multidisciplinary Approach
Recurrence patterns and postrecurrence survival after curative intent resection for pancreatic ductal adenocarcinoma
2021, Surgery (United States)
Pancreatic ductal adenocarcinoma has a high rate of recurrence after resection. We aimed to investigate patterns of recurrence of pancreatic ductal adenocarcinoma to identify opportunities for targeted intervention toward improving survival.
This was a retrospective analysis of consecutive patients that underwent curative-intent resection for pancreatic ductal adenocarcinoma between 2007 and 2015. Recurrence and survival were analyzed based on site of recurrence. Multiple clinicopathologic factors were calculated for likelihood of site-specific recurrence.
The study included 221 patients with median follow-up of 83 months. Median overall and recurrence-free survival was 19 and 13 months, respectively. Recurrence was observed in 71.9% patients. Local recurrence occurred in 16.4%, distant recurrence in 67.3%, and combined in 15.9%. The most common site of distant recurrence was the liver (49.7%) followed by lung (31.8%) and peritoneum (16.6%). Median time to liver recurrence was shortest (5 months, 95% confidence interval 1.7–8.3) and post recurrence survival was poor (4 months, 95% confidence interval 1.9–6.1). Patients with poorly differentiated tumors on pathology were 4.8 times more likely to recur in the liver (odds ratio 4.83, 95% confidence interval 1.7–13.9).
Liver metastasis after resection of pancreatic ductal adenocarcinoma occurs most frequently, earliest after surgery, and is rapidly fatal. Liver-directed therapies represent a target for future study.
Imaging and Management of Pancreatic Cancer
2020, Seminars in Ultrasound, CT and MRI
Pancreatic cancer is an aggressive disease with rising incidence and high mortality despite advances in imaging and therapeutic options. Surgical resection is currently the only curative treatment, with expanding roles for adjuvant and neoadjuvant chemoradiation. Accurate detection, staging, and post-treatment monitoring of pancreatic cancer are critical to improving survival and imaging plays a central role in the multidisciplinary approach to this disease. This article will provide a broad overview of the imaging and management of pancreatic cancer with a focus on diagnosis and staging, operative and nonoperative treatments, and post-therapeutic appearances after surgery and chemoradiation therapy.

View all citing articles on Scopus

¹: Dr. Juri Ruf, MD, Klinik für Strahlenheilkunde, Bereich Nuklearmedizin, Charité — Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, DE-13353 Berlin (Germany), Tel. +49 30 450 557127, Fax +49 30 450 557909

View full text

Detection of recurrent pancreatic cancer: Comparison of FDG-PET with CT/MRI

Abstract

Gastroenterol Clin North Am

Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer

Cancer

Gemcitabine-based therapy in pancreas cancer: Gemcitabine-docetaxel and other novel combinations

Cancer

Postoperative findings following the Whipple procedure: Determination of prevalence and morphologic abdominal CT features

Eur Radiol

Prognostic value of CA 19-9 serum course in pancreatic cancer

Hepatogastroenterology

18-FDG positron emission tomography of the pancreas: Diagnostic benefit in the follow-up of pancreatic carcinoma

Anticancer Res

Evaluation of pancreatic carcinoma with FDG PET

Abdom Imaging

Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) - Usefulness and limitations in ‚clinical reality’

Ann Nucl Med

Prospective evaluation of pancreatic tumors: Accuracy of MR imaging with MR cho-langiopancreatography and MR angiography

Radiology

Cancer of the pancreas: The best image for early detection — CT, MRI, PET or US?

Can J Gastroenterol

Oncological applications of FDG PET imaging

J Nucl Med

Diagnostic usefulness of FDG PET for pancreatic mass lesions

Ann Nucl Med